Chapter Four - Pain as a Market

CHAPTER FOUR

Pain as a Market

PAIN USED TO be subjective.

Doctors treated it based on intuition, experience, and caution. Opioids were reserved for cancer, trauma, and palliative care. They were the last resort.

But Purdue had a different vision, and it started with a single phrase:

“The Fifth Vital Sign.”

That was the branding coup.

Heart rate. Blood pressure. Temperature. Respiration. And now: pain.

It sounded scientific. Humane. Progressive. But it was a marketing slogan, one designed to expand the map. If pain was now a vital sign, it had to be monitored. Measured. Treated. Reimbursed.

And what better treatment than a powerful new opioid?

Purdue didn’t just create demand for OxyContin. They manufactured the conditions for its necessity.

They funded professional groups like the American Pain Society. They sponsored conferences and distributed pain management pamphlets to hospitals. They gave free materials to medical schools that hadn’t updated their addiction training in decades.

They pushed a narrative that under-treating pain was a moral failure, even malpractice.

They told doctors it was okay to prescribe high doses. They invented “pseudoaddiction,” a term that claimed patients who seemed addicted were actually just undertreated. The solution? More Oxy.

Purdue made pain into a measurable symptom, and Oxy into the automatic answer.

And the healthcare system took the bait.

Hospitals began scoring doctors on how well they managed pain. Insurance companies incentivized prescriptions. The federal government even tied funding to patient satisfaction, and patients in pain wanted the strongest thing available.

It worked too well.

In ERs, pain became a number. “How bad is it, from 1 to 10?”
The answer didn’t matter. The prescription did.

And OxyContin filled the gap between feeling pain and feeling heard.

It didn’t cure. It numbed. And when it wore off, it left the same pain with a little more desperation.

The system had been reprogrammed.

Doctors weren’t treating illness.
They were treating expectations.

And Purdue was cashing in on both.